Clinical Trial Update: Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of trastuzumab and gefitinib in metastatic breast cancer, and the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: COMPLETED